Harnessing the power of the immune system to destroy cancer has dominated the biotech industry over the past decade. And for good reason: CAR-T therapies, checkpoint inhibitors, oncolytic viruses, and other next-generation immunotherapies can be incredibly effective at treating cancer — in some patients.

That last phrase is the big caveat of immuno-oncology therapies: They don’t work in everyone, but only in very specific subsets of patients. While a promising way to make these therapies work in broader patient populations is to combine different immuno-oncology therapies, we first need to understand which patients will respond to treatment and why.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy